Dronedarone (Multaq): a new option in atrial fibrillation

Dronedarone (Multaq) is a new antiarrhythmic drug licensed for use in patients with nonpermanent AF. Professor John Camm and Dr Irina Savelieva highlight the results of clinical trials relating to its efficacy and adverse effects and consider its place in the treatment of AF. Copyright © 2010 Wiley Interface Ltd